CBA Florida Inc. (fka CBAI)

[MrLong]

A few years ago when I was in the Bahamas with my family I remember the locals reciting a quote: "Hey man, ya know the greatest nation on Earth? DONATION. Hahaha!!" with their hand extended looking for some $s. I was on vacation so I paid the tip and moved along. C'mon BCBSA IBC get your hands out of my pockets this is not a vacation. This is an investment not a donation. C'mon here is the BCBSA - CBAI technical ucb relationship for those who missed it for 2011:

CBAI is a (Hold) for some based on the 1/21/2011 BCBSMA Policy Updates AND the growing BCBS Independent partnerships with CBAI.

How does the BCBS partnership affect revs if we store for medical certainty? Does CBAI bill the insurer for storage of a ucb that will be transplanted within 36 months or is this service "free"? idk... Sibling donor program for a known medical condition for future transplant, I believe, is a "free" storage service to the family. So who pays the CBAI process and storage fee... insurer, shareholders, gov't? idk

Quote:
BCBSMA Revised 1/1/2011: We cover collection and storage of cord blood from a neonate when an allogeneic transplant is imminent in an identified recipient with a diagnosis that is consistent with the possible need for allogeneic transplant.
http://www.bluecrossma.com/common/en_US/medical_policies/285_Placental_Umbilical_Cord_Blood_as_a_Source_of_Stem_Cells_prn.pdf#page=1

---------- 2011 HSCT IS A CURE IN THE BCBSMA POLICY UPDATES ----------

Quote:
Key words in the new BCBSA HSCT policy "cure":
Anemia - The only definitive cure for thalassemia is to correct the genetic defect with allogeneic HSCT.
Sickle cell disease: Three major therapeutic options are available: chronic blood transfusions, hydroxyurea, and HSCT, the latter being the only possibility for cure.
SCID: Bone marrow transplant is the only definitive cure, and the treatment of choice for SCID and other primary
immunodeficiencies, including Wiskott-Aldrich syndrome and congenital defects of neutrophil function.
http://www.bluecrossma.com/common/en_US/medical_policies/190_Allogeneic_Hematopoietic_Stem_Cell_Transplantation_for_Genetic_Diseases_and_Acquired_Anemias_prn.pdf#page=4

Quote:
BCBSMA 2011 Chronic lymphocytic leukemia: Both low- and intermediate-risk CLL and SLL demonstrate relatively good prognoses with median survivals of 6 to 10 years, while the median survival of high-risk CLL or SLL may be only 2 years. CLL/SLL are rarely cured by conventional therapy. This natural history prompted investigation of HSCT as a possible "curative" regimen.
http://www.bluecrossma.com/common/en_US/medical_policies/074_Hematopoietic_Stem_Cell_Transplantation_for_Chronic_Lymphocytic_Leukemia_and_Small_Lymphocytic_Lymphoma_prn.pdf#page=1

Quote:
BCBSAMA 2011: Chronic Myelogenous Leukemia: In any case, allogeneic SCT remains the only treatment capable of inducing durable remissions or "cure" in CML patients.
http://www.bluecrossma.com/common/en_US/medical_policies/212_Hematopoietic_Stem_Cell_Transplantation_for_Chronic_Myelogenous_Leukemia_prn.pdf#page=1

----------
http://www.facebook.com/CordBloodCuresAdvocacyGroup